Semaglutide improves heart failure symptoms, improves physical capacity and causes significant weight loss in patients with heart failure with preserved ejection fraction and obesity, according to a study presented at ESC Congress 2023. These results represent the largest benefits associated with administering a therapeutic agent to obese patients with heart failure with preserved ejection fraction.
The main conclusions, after 52 weeks of therapy:
The KCCQ-CSS symptom score changed by almost 17 points in people who received semaglutide and by almost 9 points in the control group Semaglutide therapy was associated with an average change in body mass of more than 13%, while in people who had received placebo, the percentage was almost 3% The 6-minute walking distance showed a mean change of more than 21 meters in people who followed semaglutide therapy, compared to more than 1 meter in the control group Administration of semaglutide was associated decreased inflammation, reducing C-reactive protein values by almost 45% on average, compared to more than 7% in the control group NT-proBNP values decreased by almost 21% in people who received semaglutide and by more than 5% in those who received placebo Photo source: Unsplash
Among people with heart failure, about half have a preserved ejection fraction. Most of these patients are overweight or obese, excessive adipose tissue may play a role in the development and progression of heart failure with preserved ejection fraction.
The presence of obesity associates more pronounced heart failure symptoms, such as dyspnea, exercise intolerance, edema, which decreases the quality of life of these patients. Therapeutic options are limited, with no approved drugs specifically targeting the phenotype of heart failure with preserved ejection fraction associated with obesity.
Semaglutide is a GLP-1 (glucagon-like-peptide-1) receptor agonist that causes significant weight loss in overweight or obese people. The STEP-HFpEF study, which evaluates the effects of semaglutide in people with obesity and heart failure with preserved ejection fraction, is a randomized clinical trial conducted in 96 centers in 13 countries in Asia, Europe, North and South America.
Almost 530 patients with heart failure with preserved ejection fraction (over 45%), with BMI (body mass index) of at least 30, symptoms of heart failure, functional limitation and reduced exercise tolerance were included. Half of the patients received weekly semaglutide therapy for 52 weeks, and the other half received a placebo. Severe side effects were reported in more than 13% of people who received semaglutide and in almost 30% of people who received placebo.
Read also:
2023-08-28 09:58:27
#ESCCongress2023 #Semaglutide #improves #symptoms #obese #patients #heart #failure #preserved #ejection #fraction #Sentinel #report
